W2O Appoints Biopharma and Digital Marketing Leaders Jonathan Peacock and George Gallate to Board of Directors to Increase Competitive Edge and Drive Global Growth

SAN FRANCISCO--()--W2O, the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector, today announced that veteran biopharmaceutical executive Jonathan Peacock and distinguished advertising and digital marketing expert George Gallate have joined its board of directors. The appointments are intended to guide W2O’s accelerated growth plans to meet the evolving needs of its healthcare clients in a digital world and on an international scale.

Peacock has more than three decades of C-suite experience in the pharmaceutical, emerging biotech and corporate financial industries. He has held global chief financial officer (CFO) roles at Novartis and Amgen, as well as leadership positions in strategy and corporate finance at McKinsey & Company and PricewaterhouseCoopers. Gallate is rejoining the W2O board of directors. He has more than 30 years of experience in building and leading high-performing global and regional advertising and digital networks. As the former Global CEO and then Chairman of digital marketing agency giant Havas Digital, Gallate helped build the company into one of the largest digital networks globally.

“Jon and George are powerful additions to our board as we take our business to the next level to become a partner of choice for clients focused on becoming more relevant and competitive in a digital world,” said Jim Weiss, W2O Founder and CEO. “Jon has a proven track record of steering operations, strategy and business development for two of the world’s leading biopharmaceutical companies, and George has built one of the largest digital agency networks globally and guided agency alliances and partnerships with some of the world’s leading technology companies, such as Amazon and Google. Their respective insight and unmatched expertise will serve as a true asset and help guide us as we strategically build our talent pool and expand our capabilities to achieve our mission of making the world a healthier place through marketing and communications.”

During Peacock’s tenure at Amgen, the company’s share price increased by approximately 125%. While serving as CFO at Novartis Pharma, he helped increase the company’s operating profit by 40%. From 2014 to 2017, he served as Audit and Finance Committee Chair at Kite Pharma until its sale to Gilead for $11.9 billion in 2017. Following his time at Havas, Gallate served as the CEO of RKG, an independent search agency focused on the intersection of search and social, facilitating substantial revenue growth for the company throughout his tenure. He also negotiated the company’s sale to Merkle in 2014, where he then successfully served as Chief Marketing Officer for several years.

“W2O certainly lives up to its reputation of being one of, if not the most, diversified and dynamic healthcare marketing and communications firms in the industry. I continue to be impressed by the firm’s talent and use of analytics and technology to understand the evolving and ever-changing needs of healthcare companies,” said Peacock.

“As healthcare organizations and brands continue to look for new models to connect with patients, healthcare professionals and customers, W2O has distinguished itself as a premier firm when it comes to integrating analytics, creative, technology and activation skillsets into a unified delivery model that ultimately provides clients with the most high-value, breakthrough marketing and communications solutions,” said Gallate.

In June, W2O announced a new partnership with New Mountain Capital to drive growth and strengthen its relationship with clients throughout the healthcare spectrum. Since then, the company has made three acquisitions in the field of scientific and medical marketing communications and plans to pursue additional acquisitions to expand both its offerings and geographic presence.

The firm will continue to expand and enhance its board of directors, bringing in more diverse and differentiated expertise to expand its portfolio and talent.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

Contacts

W2O
Peter Duckler, 773-343-3069
pduckler@w2ogroup.com

Release Summary

W2O announced that veteran biopharma executive Jonathan Peacock and distinguished marketing expert George Gallate have joined its board of directors.

Social Media Profiles

Contacts

W2O
Peter Duckler, 773-343-3069
pduckler@w2ogroup.com